BI 3802876
Drug timelines are a Plus or Pro feature.
2 regulatory and trial events tracked for BI 3802876, covering 2025-04-09 to 2026-04-15. Get the full timeline:
Most recent: Clinical Trial Update: A Study to Test Whether BI 3802876 is Tolerated in People With Compensated Liver Cirrhosis Due to Metabolic Dysfunction- Associated Steatohepatitis (MASH) [Phase 2]